Expanded access to vepugratinib for FGFR3-altered solid tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This expanded access program provides the investigational drug vepugratinib to people with advanced cancers (especially bladder cancer) that have a specific genetic change (FGFR3 mutation) and who have run out of standard treatment options. The goal is to give access to a potential new therapy outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (bladder or other solid tumor) with a change in the FGFR3 gene.
- You have already tried all approved standard treatments, including erdafitinib for bladder cancer (if appropriate).
- You are not eligible for or cannot join the ongoing vepugratinib clinical trial.
- You are not currently enrolled in another vepugratinib study.
- You do not have a serious allergic reaction to the study drug components.
- You do not have a significant eye condition or severe heart problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
This study tests an oral medication (vepugratinib) that targets a specific gene change (FGFR3) found in some bladder cancers. It is for people with low-grade, non-invasive bladder cancer that has not spread into the muscle, to see if the drug can help control the cancer.
This program offers early access to an investigational drug called velzatinib for people with advanced GIST that has a KIT mutation. It is for patients who have run out of standard treatment options and cannot join other clinical trials.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.